CompletedNot Applicable

Efficacy and Safety of Pitavastatin/Ezetimibe After Switching From Statin Monotherapy to Pitavastatin/Ezetimibe in Patients With Hypercholesterolemia

South Korea6,927 participantsStarted 2021-12-18

Plain-language summary

A Multi-center, Open-label, Observational Study to evaluate the Efficacy and Safety of Pitavastatin/Ezetimibe after switching from Statin Monotherapy to Pitavastatin/Ezetimibe in patients with Hypercholesterolemia

Who can participate

Age range19 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Adults (≥19 years) with hypercholesterolemia. * On a stable dose of statin monotherapy for at least 8 weeks. * Scheduled to switch to Pitavastatin/Ezetimibe per investigator's decision. * Provided voluntary written informed consent. Exclusion Criteria: * Use of other lipid-lowering therapies within 4 weeks before screening. * History of clinically significant laboratory abnormalities within 1 year. * Participation in other clinical trials within 4 weeks. * Contraindications to Pitavastatin/Ezetimibe

What they're measuring

LDL-C level

Timeframe: From enrollment to the end of treatment at 24 weeks

Trial details

NCT IDNCT07445542

SponsorJW Pharmaceutical

Sponsor typeINDUSTRY

Study typeOBSERVATIONAL

Primary completion2025-05-13

View on ClinicalTrials.gov More Hypercholesterolemia trials